Nektar Therapeutics Stock (NASDAQ:NKTR), Trade Ideas

Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AADI

AIMD

AKRO

APVO

ASTR

BBAI

BCDA

BIVI

BTDR

BYND

CMCL

COIN

CRDF

CRML

DWAC

ETNB

FUFU

HSDT

IFBD

JAGX

JOAN

LIFW

MGEE

MINM

MSTR

NKTR

NYCB

OCEA

PHUN

PLTK

QNRX

RELI

RENB

RNLX

RVNC

SABR

SAVE

SBFM

SMCI

TRNR

VANI

ZJYL

Shares of  Bitdeer Technologies Group  (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

AAOI

ACGN

ADTN

AGRI

APLS

ASPN

AURC

BACK

BSFC

CFRX

CRIS

DRTT

ELIQ

FUBO

GOGO

HLLY

HRYU

HYZN

IDEX

IMGN

ITRG

KRYS

MESO

MKFG

MOXC

NKLA

OXAC

PSTX

RGTI

SAGE

SATS

SCLX

SIEN

SOHU

SOVO

SQNS

SVFD

TIVC

TMPO

TRHC

TRIB

TTOO

UPST

VRTV

VTGN

WAVD

YELL

Gainers


	Vistagen Therapeutics, Inc.  (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.


Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Biotech

Equities

Health Care

General

Nektar Therapeutics Inc (NASDAQ: NKTR) said its former partner Eli Lilly And Co (NYSE: LLY) had presented &#34;erroneous data&#34; from two Phase 1b studies of its atopic dermatitis drug, 

Why Is Nektar Therapeutics Stock Surging Today?

To regain compliance with the Minimum Bid Price Requirement, the Company&rsquo;s common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business days. This requirement was met on April 16, 2024.

Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing

<h3>Gainers</h3>
<ul>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares moved upwards by 70.5% to $2.78 during Thursday's regular session. The company's market cap stands at $105.1 million. </li>
<li>Eliem Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>) shares rose 57.3% to $4.2. The market value of their outstanding shares is at $116.4 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 40.58% to $7.17. The market value of their outstanding shares is at $210.4 million. </li>
<li>Alpine Immune Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALPN#NASDAQ">ALPN</a>) stock moved upwards by 36.84% to $64.37. The company's market cap stands at $4.2 billion. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares moved upwards by 29.51% to $0.15. The company's market cap stands at $1.8 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 25.57% to $1.62. The market value of their outstanding shares is at $297.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 57.9% to $1.01 during Thursday's regular session. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) shares declined by 30.61% to $10.02. The market value of their outstanding shares is at $257.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 25.35% to $1.5. The market value of their outstanding shares is at $14.0 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock decreased by 20.07% to $1.22. The company's market cap stands at $17.9 million. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock declined by 15.19% to $6.57. The market value of their outstanding shares is at $70.5 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock decreased by 14.63% to $0.75. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

AKAN

ALPN

BSGM

CADL

ELYM

LTRN

RCEL

RLYB

12 Health Care Stocks Moving In Thursday's Intraday Session

Jefferies analyst Roger Song maintains Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Hold and raises the price target from $0.5 to $1.

Price Target

Analyst Ratings

Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
Rezpegaldesleukin (REZPEG) is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional T reg cells and engaging multiple immunoregulatory pathways.&nbsp;
"The start of this Phase 2b study is another significant milestone for Nektar as we advance REZPEG, a potentially transformative new mechanism for alopecia areata and other auto-immune disorders," said Mary Tagliaferri, M.D., Chief Medical Officer at Nektar Therapeutics. "Alopecia areata is a disease where a patient's own immune system attacks hair follicles and the resulting hair loss can be devastating for patients.&nbsp; Current treatments available have high relapse rates and carry potential safety challenges. As a result, there is a high unmet need for durable and well-tolerated treatment options that target the underlying dysfunction of the immune system in these patients. We believe there's an opportunity for REZPEG to emerge as a novel biologic mechanism for alopecia patients and we look forward to our topline data from this study expected in the first half of 2025."
Nektar's global, randomized, double-blind, placebo-controlled, dose-ranging Phase 2b study will investigate the efficacy and safety of REZPEG in 84 participants with severe to very severe alopecia areata over a 36-week induction treatment period. The induction treatment period will compare two different dosing regimens of REZPEG against placebo. Participants will be followed for an additional 24 weeks after the end of the treatment period to evaluate durability. Initial results from the study are anticipated in the first half of 2025.
The primary efficacy endpoint will evaluate mean percent improvement in the Severity of Alopecia Tool (SALT) at week 36. Secondary endpoints include proportion of participants with greater than or equal to 50% reduction in SALT at week 36 and other assessed timepoints and mean percent improvement in SALT at other assessed timepoints.

Nektar Therapeutics Announces Initiation Of Phase 2b Clinical Study Evaluating Rezpegaldesleukin In Patients With Severe To Very Severe Alopecia Areata

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. The company reported quarterly sales of $23.89 million which beat the analyst consensus estimate of $18.05 million by 32.29 percent. This is a 8.45 percent increase over sales of $22.02 million the same period last year.

Earnings

Earnings Beats

Nektar Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.23) Estimate, Sales $23.89M Beat $18.05M Estimate

Shares of Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) rose sharply during Monday&rsquo;s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>BitFuFu Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fufu#NASDAQ">FUFU</a>) shares jumped 107% to $13.20 amid volatility following the company&#39;s recent business combination with Arisz Acquisition Corp and listing on the Nasdaq.</li>
<li>Quoin Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qnrx#NASDAQ">QNRX</a>) climbed 89% to $5.31 after the company announced FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) gained 52.8% to $1.5890 after the company announced that it received an unsolicited approach from a publicly listed strategic diagnostics company.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) climbed 42.7% to $10.11. Phunware is expected to report fourth-quarter results on March 12, 2024.</li>
<li>Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) gained 39.4% to $1.4650.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) shares climbed 38.2% to $0.1223 after surging 50% on Friday.</li>
<li>Cardiff Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crdf#NASDAQ">CRDF</a>) rose 31.6% to $3.83 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) gained 31.3% to $4.94. E.W. Scripps Director Charles L. Barmonde acquired a total of 10,500 shares an average price of $4.28.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsdt#NASDAQ">HSDT</a>) climbed 30% to $5.91. Helius Medical Technologies announced it secured HCPCS codes for portable neuromodulation stimulator mouthpiece and controller.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) gained 27% to $1.14. Kineta recently announced a restructuring and the exploration of strategic alternatives.</li>
<li>BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) rose 25% to $4.3472.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) gained 24.4% to $12.44.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) gained 22% to $2.44.</li>
<li>Reliance Global Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reli#NASDAQ">RELI</a>) rose 21.7% to $0.6299 after gaining 11% on Friday.</li>
<li>Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) climbed 21.1% to $33.69 after gaining 3% on Friday.</li>
<li>89bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etnb#NASDAQ">ETNB</a>) gained 20.3% to $15.18.</li>
<li>Nektar Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktr#NASDAQ">NKTR</a>) gained 19.4% to $0.9315. Nektar Therapeutics announced a $30 million private placement financing with TCGX.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) shares gained 18.9% to $1,076.45. Super Micro Computer will join the S&amp;P 500 Index, effective March 18, S&amp;P Dow Jones Indices, a division of S&amp;P Global, said in a release.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 17.8% to $1,271.51 amid strength in Bitcoin.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) rose 16.3% to $20.95 after Arkhouse and Brigade Capital increased their offer to acquire Macy&#39;s to $24 per share.</li>
<li>Renovaro Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/renb#NASDAQ">RENB</a>) gained 14.3% to $2.64.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) gained 13.4% to $44.18 after falling over 5% on Friday.</li>
<li>MGE Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgee#NASDAQ">MGEE</a>) rose 12% to $70.75. MGE Energy will replace iRobot in the S&amp;P SmallCap 600.</li>
<li>BGC Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgc#NASDAQ">BGC</a>) gained 11.8% to $7.93. BGC Group is set to join S&amp;P SmallCap 600.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) climbed 11.6% to $7.10.</li>
<li>H&amp;R Block, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrb#NYSE">HRB</a>) gained 8.9% to $52.08.</li>
<li>Aadi Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aadi#NASDAQ">AADI</a>) shares surged 8.8% to $2.0899 after the company announced publication of long-term efficacy and safety data further supporting FYARRO&reg; for the treatment of malignant PEComa.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares rose 7.7% to $1.11. LifeWallet announced a comprehensive settlement with 28 affiliated property and casualty insurers, benefiting LifeWallet&rsquo;s <a href="https://www.benzinga.com/money/best-medicare-advantage-plans/">medicare</a> clients across the U.S.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) climbed 7.5% to $221.11 amid a rise in the price of Bitcoin.</li>
<li>Box, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/box#NYSE">BOX</a>) gained 6.6% to $28.30. Box will replace Forrester Research Inc in the S&amp;P SmallCap 600.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioVie Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bivi#NASDAQ">BIVI</a>) fell 42.7% to $1.0830 after the company reported pricing of public offering.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) fell 38.7% to $ .3102&nbsp;following a report suggesting the company may file for bankruptcy soon.</li>
<li>Astra Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astr#NASDAQ">ASTR</a>) dipped 35% to $0.8598.</li>
<li>BioCardia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcda#NASDAQ">BCDA</a>) fell 23.3% to $0.4449 after reporting interim results from Phase III CardiAMP cell therapy heart failure trial.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) declined 21.8% to $2.00.</li>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) declined 21.7% to $2.4199. Vivani Medical recently announced the pricing of a $15 million registered direct offering of common stock and warrants.</li>
<li>Interactive Strength Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trnr#NASDAQ">TRNR</a>) tumbled 19.8% to $0.40. Interactive Strength recently announced it has entered into an exclusive worldwide distribution agreement with WOODWAY to sell and distribute CLMBR.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) dipped 19.3% to $5.03</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) fell 18.4% to $4.7395 after jumping 35% on Friday.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) fell 16.6% to $16.78. Avidity Biosciences announced new long-term AOC 1001 data from the Marina-OLE trial showing reversal of disease progression in Myotonic Dystrophy Type 1 patients across multiple endpoints.</li>
<li>Playtika Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pltk#NASDAQ">PLTK</a>) fell 14.8% to $6.44</li>
<li>Aptevo Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apvo#NASDAQ">APVO</a>) declined 14.7% to $0.1399.</li>
<li>J-Long Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jl#NASDAQ">JL</a>) shares dipped 14.3% to $1.98 after jumping over 15% on Friday. J-Long Group recently declared a special cash dividend in aggregate amount of $6 million.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) fell 14.3% to $0.0474. Sunshine Biopharma, last month, announced closing of $10.0 million underwritten public offering.</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) fell 13.6% to $3.0650 after the company announced that it identified material weaknesses in its internal controls related to internal loan review, that resulted from ineffective oversight, risk assessment and monitoring activities.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) fell 12.1% to $5.68 after the company announced the termination of its merger agreement with JetBlue.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) fell 11.6% to $2.3050. Sabre announced exchange of $150 million of existing 4.000% exchangeable senior notes due 2025 for exchangeable senior notes due 2026.</li>
<li>Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) fell 11.6% to $38.49. B of A Securities analyst Ming Hsun Lee maintained Li Auto with a Buy and raised the price target from $57 to $60.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) fell 11.2% to $6.20. Revance announced pricing of $100 million public offering of 16 million shares of common stock at a price of $6.25 per share.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) dipped 11.3% to $8.67 after the company announced that it was unable to file its annual report due to technical difficulties in assembling the submission for filing. Also, the company said it anticipates it will seek to raise additional capital in 2024.</li>
<li>Caledonia Mining Corporation Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmcl#NASDAQ">CMCL</a>) shares tumbled 9.6% to $9.29 after the company issued a trading update for the year ended Dec. 31, 2023.</li>
<li>Hertz Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/htz#NYSE">HTZ</a>) fell 7.2% to $7.26.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) fell 6.9% to $5.38.</li>
</ul>
&nbsp;
Now Read This: <a href="	https://www.benzinga.com/trading-ideas/long-ideas/24/03/37454953/charles-colvard-and-3-other-penny-stocks-insiders-are-buying"> Charles &amp; Colvard And 3 Other Penny Stocks Insiders Are Buying </a>

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

WIIM

Nektar Therapeutics shares are trading higher after the company announced $30 million in private placement financing with TCGX.

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the "PIPE") for gross proceeds of $30 million, before deducting expenses.
In the PIPE, Nektar is selling 25 million shares of its common stock, in the form of a pre-funded warrant, at a price of $1.20 per share, representing a premium of approximately 80% to Nektar's 30-day volume-weighted average price. The pre-funded warrant will have an exercise price of $0.0001 per share and will not expire.
The PIPE is expected to close on or before March 6, 2024, subject to customary closing conditions. Nektar has agreed to submit a registration statement filing for the underlying Common Stock no later than 90 days after the closing.
"We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata," said Howard Robin, President and Chief Executive Officer of Nektar Therapeutics. "We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
Rezpegaldesleukin is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional T reg cells and engaging multiple immunoregulatory pathways.&nbsp;
The private placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506 of Regulation D of the Securities Act of 1933, as amended and in reliance on similar exemptions under applicable state laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Offerings

Nektar Therapeutics Announces $30M Private Placement Financing With TCGX; Nektar Is Selling 25M Shares Of Its Common Stock, In The Form Of A Pre-Funded Warrant, At A Price Of $1.20 Per Share

<h3>Companies Reporting Before The Bell</h3>
&bull; Sohu.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>) is estimated to report earnings for its fourth quarter.
&bull; Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is projected to report quarterly loss at $0.29 per share on revenue of $18.11 million.
&bull; LENSAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>) is expected to report quarterly loss at $0.22 per share on revenue of $12.00 million.
&bull; Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is projected to report quarterly loss at $0.27 per share on revenue of $3.53 billion.
&bull; Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is estimated to report quarterly earnings at $2.35 per share on revenue of $172.02 million.
&bull; Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is likely to report earnings for its fourth quarter.
&bull; GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is estimated to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $18.05 million.
&bull; Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $4.77 million.
&bull; ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISH#NASDAQ">WISH</a>) is likely to report quarterly loss at $2.66 per share on revenue of $53.06 million.
&bull; Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is expected to report quarterly earnings at $0.45 per share on revenue of $27.41 million.
&bull; Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $317.48 million.
&bull; Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is likely to report quarterly loss at $0.25 per share on revenue of $9.00 million.
&bull; Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $274.41 million.
&bull; Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $226.24 million.
&bull; Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $157.42 million.
&bull; Northwest Pipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWPX#NASDAQ">NWPX</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $107.35 million.
&bull; Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $607.02 million.
&bull; Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $330.85 million.
&bull; Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is expected to report quarterly loss at $0.07 per share on revenue of $7.70 million.
&bull; SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $83.11 million.
&bull; Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) is expected to report quarterly loss at $0.27 per share on revenue of $25.89 million.
&bull; ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) is likely to report quarterly loss at $0.13 per share on revenue of $80.33 million.
&bull; AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is estimated to report quarterly earnings at $0.33 per share on revenue of $170.62 million.
&bull; Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) is estimated to report quarterly loss at $0.41 per share on revenue of $9.42 million.
&bull; GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $158.21 million.
&bull; Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $65.92 million.
&bull; Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) is expected to report earnings for its fourth quarter.
&bull; Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) is likely to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AKYA

AVAV

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

CARA

CRGY

CVGI

EKSO

EOSE

GTLB

LNSR

NWPX

RBOT

SEMR

SFIX

SLND

STXS

TDUP

VATE

WISH

Earnings Scheduled For March 4, 2024

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is set to give its latest quarterly earnings report on Monday, 2024-03-04. Here's what investors need to know before the announcement.
Analysts estimate that Nektar Therapeutics will report an earnings per share (EPS) of $-0.21. 
Nektar Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 8.76% drop in the share price the next day.
Here's a look at Nektar Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.20</td>
<td>-0.28</td>
<td>-0.25</td>
<td>-0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.19</td>
<td>-0.27</td>
<td>-0.25</td>
<td>-0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709308837_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Nektar Therapeutics were trading at $0.71 as of February 29. Over the last 52-week period, shares are down 49.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NKTR/earnings">To track all earnings releases for Nektar Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nektar Therapeutics Earnings Preview

<h3>Gainers</h3>
<ul>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 21.6% to $3.82 during Friday's after-market session. The company's market cap stands at $3.2 million. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares rose 10.61% to $4.95. The market value of their outstanding shares is at $248.5 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) stock moved upwards by 9.77% to $4.38. The market value of their outstanding shares is at $407.0 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares rose 8.71% to $0.29. The company's market cap stands at $7.0 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) stock increased by 7.94% to $0.62. The company's market cap stands at $33.5 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares moved upwards by 6.44% to $0.46. The market value of their outstanding shares is at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) stock decreased by 21.4% to $0.28 during Friday's after-market session. The market value of their outstanding shares is at $11.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares declined by 10.57% to $1.1. The market value of their outstanding shares is at $38.7 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock declined by 6.41% to $0.5. The market value of their outstanding shares is at $95.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares decreased by 5.17% to $0.31. The company's market cap stands at $15.1 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares fell 5.05% to $1.13. The company's market cap stands at $18.0 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares fell 5.03% to $0.45. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

ACON

BCEL

BCLI

CNTX

ESLA

MNPR

PCSA

REVB

12 Health Care Stocks Moving In Friday's After-Market Session

Nektar And Collaborators Present Preclinical Data On NKTR-255 Combined With Obinutuzumab In Poster Presentation At The 65th ASH Annual Meeting

JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Underweight.

Initiation

JP Morgan Reinstates Underweight on Nektar Therapeutics

TD Cowen analyst Chris Shibutani upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Market Perform to Outperform.

Upgrades

TD Cowen Upgrades Nektar Therapeutics to Outperform

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported its Q3 earnings results on Tuesday, November 7, 2023 at 04:22 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Nektar Therapeutics beat estimated earnings by 5.0%, reporting an EPS of $-0.19 versus an estimate of $-0.2.
Revenue was up $519 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 8.94% drop in the share price the next day.
Here's a look at Nektar Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.28</td>
<td>-0.25</td>
<td>-0.45</td>
<td>-0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.27</td>
<td>-0.25</td>
<td>-0.32</td>
<td>-0.31</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>21.83M</td>
<td>19.84M</td>
<td>22.13M</td>
<td>22.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>20.50M</td>
<td>21.59M</td>
<td>22.02M</td>
<td>23.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Nektar Therapeutics <a href="https://www.benzinga.com/quote/NKTR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Nektar Therapeutics Q3 Earnings

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here's what investors need to know before the announcement.
Analysts estimate that Nektar Therapeutics will report an earnings per share (EPS) of $-0.20. 
Nektar Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 8.94% drop in the share price the next day.
Here's a look at Nektar Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.28</td>
<td>-0.25</td>
<td>-0.45</td>
<td>-0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.27</td>
<td>-0.25</td>
<td>-0.32</td>
<td>-0.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.94%</td>
<td>-2.42%</td>
<td>9.42%</td>
<td>5.9%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699300930_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Nektar Therapeutics were trading at $0.55 as of November 03. Over the last 52-week period, shares are down 86.02%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/NKTR/earnings">To track all earnings releases for Nektar Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Nektar Therapeutics's Earnings

– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
– New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQI and POEM Endpoints –
SAN FRANCISCO, Oct. 13, 2023 &nbsp;/PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, in patients with atopic dermatitis (AD) at the 2023 European Academy of Dermatology and Venereology (EADV) Congress. These data were presented by Dr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Director of Clinical Research and Contact Dermatitis in a late-breaking oral presentation.
"Data from this presentation demonstrate consistent benefit with REZPEG across multiple clinician and patient-reported outcomes, which were maintained through 36 weeks after treatment ended," said Dr. Jonathan Silverberg. "The sustained post-treatment benefit observed with REZPEG has the potential to alter the need for frequent maintenance dosing for patients with atopic dermatitis. Together with the observed safety profile, these promising results potentially open the door for a new therapeutic class."
In the Phase 1b study, patients with moderate-to-severe AD that were treated with REZPEG showed dose-dependent improvements in Eczema Area and Severity Index (EASI), Validated Investigator Global Assessment (vIGA), Body Surface Area (BSA), and Itch Numeric Rating Scale (NRS) over 12 weeks of treatment compared to placebo, which were sustained post-treatment over an additional 36 weeks. At the highest studied dose, the proportion of Daily Life Quality Index (DLQI) responders was 75% and the proportion of Patient Oriented Eczema Measure (POEM) responders was 65% at week 12. The proportion of responders were generally sustained after treatment ended through the 36-week follow-up. This durability highlights REZPEG's disease remittive potential.
REZPEG was well tolerated with no patients in the REZPEG groups experiencing severe, serious, or fatal adverse events, and no anti-REZPEG antibodies were detected. Pharmacodynamic data observed in the Phase 1b study corroborate the clinical efficacy signal observed in patients. Compared with placebo, there were sustained increases in absolute numbers of circulating total (FoxP3+CD25+) and CD25bright Tregs in the REZPEG treatment arms. The peak increase in CD25bright Treg number was 10-fold above baseline in the 24 µg/kg group.
Based on these data, the company is initiating two Phase 2 studies in atopic dermatitis and in alopecia areata. These trials are expected to initiate in October of this year and in early 2024, respectively. The trial design for the study in patients with moderate-to-severe atopic dermatitis was presented in an ePoster at EADV earlier this week.
"The findings presented today confirm our previously-reported data demonstrating the efficacy and rapid onset of action of REZPEG and continue to reinforce the promise of REZPEG as a novel therapeutic for patients with moderate-to-severe atopic dermatitis," said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Research &amp; Development Officer at Nektar. "We look forward to advancing the program into our robust Phase 2b study in this indication and exploring its therapeutic potential in other autoimmune indications, including alopecia areata."
Highlight of the new patient-reported outcomes for the Phase 1b study in atopic dermatitis presented at EADV 2023 for the first time:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3" rowspan="1">Proportion of Patients&nbsp;Who Achieved a DLQI Greater than or Equal to a 4-point Reduction from Baseline (NRI&#x2A; calculation)&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Study Arm</td>
<td colspan="1" rowspan="1">12 weeks</td>
<td colspan="1" rowspan="1">48 weeks</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Placebo</td>
<td colspan="1" rowspan="1">30&nbsp;%</td>
<td colspan="1" rowspan="1">33&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">12 μg/kg</td>
<td colspan="1" rowspan="1">46&nbsp;%</td>
<td colspan="1" rowspan="1">25&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">24 μg/kg</td>
<td colspan="1" rowspan="1">75% (p = 0.0426) &nbsp;</td>
<td colspan="1" rowspan="1">56&nbsp;%</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&#x2A;NRI: non-responder imputation</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3" rowspan="1">Proportion of Patients Who Achieved a POEM Greater than or Equal to a 4-point Reduction from Baseline (NRI&#x2A; calculation)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Study Arm</td>
<td colspan="1" rowspan="1">12 weeks</td>
<td colspan="1" rowspan="1">48 weeks</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Placebo</td>
<td colspan="1" rowspan="1">30&nbsp;%</td>
<td colspan="1" rowspan="1">33&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">12 μg/kg</td>
<td colspan="1" rowspan="1">50&nbsp;%</td>
<td colspan="1" rowspan="1">22&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">24 μg/kg</td>
<td colspan="1" rowspan="1">65&nbsp;%</td>
<td colspan="1" rowspan="1">70&nbsp;%</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&#x2A;NRI: non-responder imputation</td>
</tr>
</tbody>
</table>
</figure>
Details of the presentations at&nbsp;EADV are as follows:
Efficacy and Safety of Single Agent Rezpegaldesleukin, a Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from a Randomized Phase 1b Study&nbsp;(Abstract #6685, Session:&nbsp;DT301.3: Late Breaking News. Friday, October 13, 14:30 – 14:45 CET)
A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis&nbsp;(Abstract #6218/ePoster #P0559. Trial in Progress)
2023 EADV presentations are available for download at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3994475-1&amp;h=2625831450&amp;u=http%3A%2F%2Fwww.nektar.com%2Fscience%2Fscientific-posters&amp;a=http%3A%2F%2Fwww.nektar.com%2Fscience%2Fscientific-posters">http://www.nektar.com/science/scientific-posters</a>.

Events

Nektar Presents New Responder Data For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy, In Late-Breaking News Oral Presentation At 2023 EADV Congress

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation –
Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress&nbsp;to be held October 11-14 in Berlin. REZPEG&nbsp;is in Phase 2 development for the treatment of atopic dermatitis and for the treatment of alopecia areata.
<a href="https://mma.prnewswire.com/media/1390052/nektar_logo.html"><img src="https://mma.prnewswire.com/media/1390052/nektar_logo.jpg" alt="(PRNewsfoto/Nektar Therapeutics)" /></a>
"We are honored to be selected by EADV to present our late-breaking Phase 1b data for REZPEG and our Phase 2b study design in patients with moderate to severe atopic dermatitis," said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Research &amp; Development Officer at Nektar. "The presentations highlight the momentum and strength of our REZPEG program and, in particular, its potential as a remittive therapy for patients with atopic dermatitis. We look forward to advancing the program into our robust Phase 2b study in biologic-naïve patients with moderate to severe atopic dermatitis later this month."
Details of the presentations at EADV are as follows:
Efficacy and Safety of Single Agent Rezpegaldesleukin, a Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from a Randomized Phase 1b Study&nbsp;(Abstract #6685, Session:&nbsp;DT301.3: Late Breaking News. Friday, October 13, 14:30 – 14:45 CET)
Authors: Jonathan Silverberg1, David Rosmarin2, Raj Chovatiya3, Stephen Schleicher4, Leon Kircik5,6, Timothy Rodgers7, Sohail Chaudhry8, Christie Fanton8, Danni Yu8, Yi Liu8, Brian Kotzin8, Mary Tagliaferri8, Carsten Schmitz9, Ajay Nirula9, Jonathan Zalevsky8
Affiliations: 1Department Of Dermatology, George Washington University School Of Medicine, Washington, DC, United States; 2Indiana University School of Medicine, Indianapolis, IN, United States; 3Feinberg School Of Medicine, Northwestern University, Chicago, IL, United States; 4DermDox Centers for Dermatology, Sugarloaf, PA, United States; 5Icans School of Medicine at Mt. Sinai, New York, NY, United States; 6Skin Sciences, PLLC, Louisville, KY, United States; 7Rodgers Dermatology, Frisco, TX, United States; 8Nektar Therapeutics, San Francisco, CA, United States; 9Eli Lilly and Company, Indianapolis, IN, United States.
A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis&nbsp;(Abstract #6218/ePoster #P0559. Trial in Progress)
Authors: Jonathan Silverberg1, Raj Chovatiya2, David Rosmarin3, Lisa Beck4, Melinda Gooderham5, Andrew Blauvelt6, Stephen Schleicher7, Sohail Chaudhry8, Christie Fanton8, Danni Yu8, Yi Liu8, Zachary Lee8, Mario Marcondes8, Brian Kotzin8, Mary Tagliaferri8, Jonathan Zalevsky8, Thomas Bieber9
Affiliations: 1Department Of Dermatology, George Washington University School Of Medicine, Washington, DC, United States; 2Feinberg School Of Medicine, Northwestern University, Chicago, IL, United States; 3Indiana University School of Medicine, Indianapolis, IN, United States; 4University Of Rochester Medical Center, Rochester, NY, United States; 5Department of Medicine, Queen's University, Kingston, ON, Canada; 6Oregon Medical Research Center, Portland, United States; 7DermDox Centers for Dermatology, Sugarloaf, PA, United States; 8Nektar Therapeutics, San Francisco, CA, United States; 9Christine Kühne Center For Allergy Research And Education, University Of Bonn, Bonn, Germany
2023 EADV presentations will be available for download after each session <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3984996-1&amp;h=310840467&amp;u=http%3A%2F%2Fwww.nektar.com%2Fscience%2Fscientific-posters&amp;a=http%3A%2F%2Fwww.nektar.com%2Fscience%2Fscientific-posters">http://www.nektar.com/science/scientific-posters</a>.
About REZPEG
Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body's self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. REZPEG is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. It targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, REZPEG may act to bring the immune system back into balance.
REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. It is wholly-owned by&nbsp;Nektar Therapeutics.

Nektar Therapeutics Announces Two Abstracts Accepted At EADV Congress 2023 For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy

Nektar Therapeutics Announces New Clinical Study Collaboration With Cellular Biomedicine Group Inc. to Evaluate NKTR-255 In Combination With C-TIL051 In Advanced Non-Small Cell Lung Cancer

SCOTT GREER, Director at Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), reported a large acquisition of company stock options on September 22, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000906709/000120919123050330//Archives/edgar/data/906709/000120919123050330/0001209191-23-050330-index.htm">U.S. Securities and Exchange Commission</a> on Friday showed that GREER, Director at Nektar Therapeutics, a company in the Health Care sector, was just awarded stock options worth 85,000 shares of NKTR. The options give GREER the right to buy the company's stock at $0.68 per share.
Nektar Therapeutics shares are trading down 3.34% at $0.64 at the time of this writing on Friday morning. Since the current price is $0.64, this makes GREER's 85,000 shares worth $54,442.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000906709">Check Out The Full List Of Nektar Therapeutics's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Director at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 Shares

Nektar Therapeutics Q4 2023 Earnings Preview

Today, several major companies are expected to report earnings: AeroVironment (AVAV), Avadel Pharmaceuticals (AVDL), Global Ship Lease (GSL), Nekta...

Options Volatility and Implied Earnings Moves Today, March 04, 2024

Nektar Therapeutics enters into a $30M private placement financing agreement

Nektar Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M

Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript

Nektar Therapeutics (NKTR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Nektar Therapeutics faces a significant busi...

Nektar Therapeutics Is Worried About This – Should You Be Worried Too?